Withdrawn application: Ontilyv, 12/03/2024
Submitted by Anonymous (not verified) on 18 September 2024 - 12:00
Withdrawn application: Ontilyv, 12/03/2024
Withdrawn application: Ongentys, 12/03/2024
Submitted by Anonymous (not verified) on 18 September 2024 - 11:45
Withdrawn application: Ongentys, 12/03/2024
Herbal medicinal product: Absinthii herbaArray, F: Assessment finalised
Submitted by Anonymous (not verified) on 18 September 2024 - 10:20
Herbal medicinal product: Absinthii herbaArray, F: Assessment finalised
Human medicines European public assessment report (EPAR): Pomalidomide Accord, pomalidomide, Date of authorisation: 26/07/2024, Status: Authorised
Submitted by Anonymous (not verified) on 17 September 2024 - 15:40
Human medicines European public assessment report (EPAR): Pomalidomide Accord, pomalidomide, Date of authorisation: 26/07/2024, Status: Authorised
Human medicines European public assessment report (EPAR): Kerendia, finerenone, Date of authorisation: 16/02/2022, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 17 September 2024 - 15:01
Human medicines European public assessment report (EPAR): Kerendia, finerenone, Date of authorisation: 16/02/2022, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Vemlidy, tenofovir alafenamide, Date of authorisation: 09/01/2017, Revision: 17, Status: Authorised
Submitted by Anonymous (not verified) on 17 September 2024 - 14:43
Human medicines European public assessment report (EPAR): Vemlidy, tenofovir alafenamide, Date of authorisation: 09/01/2017, Revision: 17, Status: Authorised
Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (18 September 2024)
Submitted by Anonymous (not verified) on 17 September 2024 - 13:03
Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (18 September 2024)
Pharmacovigilance Risk Assessment Committee (PRAC) criteria to prioritise impact research (Rev.1)
Submitted by Anonymous (not verified) on 17 September 2024 - 12:54
Pharmacovigilance Risk Assessment Committee (PRAC) criteria to prioritise impact research (Rev.1)
Veterinary medicines European public assessment report (EPAR): Dexdomitor, dexmedetomidine, Status: Authorised
Submitted by Anonymous (not verified) on 17 September 2024 - 12:40
Veterinary medicines European public assessment report (EPAR): Dexdomitor, dexmedetomidine, Status: Authorised
Recommended submission dates for veterinary medicinal products
Submitted by Anonymous (not verified) on 17 September 2024 - 10:30
Recommended submission dates for veterinary medicinal products